UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
A shortage of late-stage capital pushes the biggest prizes into US hands

Life sciences should be a natural place to look for growth

Drugs developed in Asian nation are increasingly being used to seed US start-ups

Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs

Groups will need to buy mature biotechs to replace revenue lost to generic competitors

Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential

Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022